Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNotebook: Four deal updates, a venture funding round and a milestone fee

This article was originally published in Scrip

Executive Summary

TG Therapeutics signs a study partner; Editas completes patent deals; J&J adds two collaborators; Allena raises $25m Series B; and CTI earns Trisenox milestone fee.

You may also be interested in...



BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight

Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.

Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib

Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel